Opportunities to Support Covid-19 and Metabolic Drugs

Abstract

In an open short-term study, 80 people were selected with coronaviral infection- caused pneumonia and heart disease; 59 persons from them received Mildronate as a metabolic support,18 similar comorbid patients received only standard therapy. In addition to standard studies, patients had an assessment of the levels of C-reactive protein (CRP), D-dimer, creatinine, lactate dehydrogenase on the first day of hospitalization and at discharge. The duration of hospitalization, the dynamics of symptoms of cardiovascular diseases according to the scale for assessing the clinical status of a patient with CHF scale, the severity of asthenia according to the MFI- 20 scale, and the quality of life according to the EQ-5D scale were estimated.

There was fixed a decrease in hospitalization time in the Mildronate group comparatively to the control group; the difference was statistically significant (p≤0,01). Laboratory indicators and their dynamics did not have significant differences between the groups, however, in the group receiving Mildronate, there was a significant (p≤0,01) decrease in the level of CRP and D-dimer by the time of discharge. The results of the estimation on SHOKS, MFI-20, EQ-5D scales did not show statistically significant differences between patients in the groups during hospitalization, however, after 3 months in the Mildronate group there was a significant improvement in the quality of life (p≤0,01), a decrease in clinical manifestations of chronic heart failure on the SHOKS scale (p≤0,01), as well as manifestations of asthenia (p≤0,01).

In this work, for the first time, the complex effect of Mildronate is shown in improving not only the parameters of metabolism, the hemostasis system, clinical manifestations of chronic heart failure, but also reducing the severity of symptoms, the first stage with severe post-infectious asthenia.